Sabrina McGuigan

Director, Franchise Operations, Global Rare Diseases Sanofi

Sabrina is a strategic, results-driven leader with over 20 years of experience translating complex medical and behavioral data into actionable initiatives across marketing, medical education, and scientific communications. With a deep focus on healthcare professional (HCP) engagement, she excels at uncovering the hidden drivers behind disease awareness and clinical behavior to inform impactful programming.

Her career spans the launch of more than 20 brands across diverse therapeutic areas, with a particular passion for rare diseases. Sabrina bridges molecular science with clinical relevance to address unmet medical needs—developing brand lexicons, scientific communication platforms, multidisciplinary advisory boards, and MSL training programs that ensure alignment across teams.

Currently serving as Director of Franchise Operations for Global Rare Diseases at Sanofi, Sabrina previously held roles at Takeda Pharmaceuticals (Global Medical Communications Lead, Rare GI) and PTC Therapeutics (Director of Global Medical Communications), where she led cross-functional pipeline efforts spanning rare pediatric neuromuscular diseases and oncology.

Sabrina holds an MBA in Marketing from the Johns Hopkins Carey Business School. And beyond her professional work, she is a Wish Granter for Make-A-Wish, a mentor for 100 Roses from Concrete, and President of the New York chapter of the Healthcare Businesswomen's Association.

Pharma Launch Excellence Summit Conference Day 1: Wednesday September 30

8:15 AM Chairs Opening Remarks - Aligning the Enterprise & De-Risking Launch

Day 1: Aligning the Enterprise & De-Risking Launch

In 2026, launch excellence is moving beyond product positioning to shaping the disease space, building ecosystem readiness, and aligning development, access and commercial execution earlier.

1:30 PM Panel Discussion: Defining Launch Success - Speed, Access or Impact?

With competing priorities across functions, defining success is increasingly complex.

This session will delve into how a range of pharma companies are redefining launch success through:

• Balancing speed, access, engagement and revenue

• Aligning KPIs across teams

• Measuring short and long-term success

2:30 PM Roundtable Discussion Groups

Small groups. No slides. No spectators.

Each table is built around a problem teams are actively trying to solve:

• Fixing weak uptake in the first 90 days post-launch

• Getting Medical, Access and Commercial aligned before approval

• What to cut when launch budgets tighten

• Where AI is actually saving time in launch execution

• Dealing with payer pushback on high-cost therapies

You'll leave with:

• How others are approaching it

• What's working vs failing

• Practical ideas you can take straight back

Rountables Include:

AI in Launch: Turning Experimentation into Measurable Impact
Access, Pricing and Affordability as Launch Strategy]
Medical Affairs, Evidence and Scientific Engagement Before Launch
Turning Launch Strategy into Launch Performance
Field Execution, Commercial Ops and Launch Infrastructure

5:30 PM Chairs Wrap-Up & End of Conference Day 1

Pharma Launch Excellence Summit Conference Day 2: Thursday October 1

8:15 AM Chair's Opening Remarks - Day 2 - Driving Execution, Adoption & Performance

Driving Execution, Adoption & Performance

11:30 AM Presentation / Case Study: When You're No Longer the Gold Standard: Rebuilding Relevance in a Shifting Market

Being first, best-known or historically dominant in a category does not guarantee continued leadership. As competitors enter, standards evolve and new evidence reshapes HCP expectations, launch teams must work harder to protect equity, maintain visibility and keep the patient at the center of the story.

Drawing on experience in diabetes & COPD launch strategy, this session will explore how teams can respond when a legacy brand or established standard begins to lose its automatic leadership position, and how to build a new relevance strategy that connects product value, patient need, HCP confidence and field execution.

• Protecting brand equity when the category benchmark begins to shift

• Maintaining HCP visibility as competitor narratives gain momentum

• Reconnecting the product story to patient need and treatment value

• Aligning Medical, Commercial and Field around renewed category relevance

4:00 PM Closing Remarks & End of Conference

Check out the incredible speaker line-up to see who will be joining Sabrina.

Download The Latest Agenda

In Partnership With:

QUESTIONS?

Address: IQPC Ltd, 129 Wilton Road,
London SW1V 1JZ
Telephone: 44 (0) 207 368 9300
Fax: 44 (0) 207 368 9301
Email: enquire@iqpc.co.uk